Strain differences in estrogen-induced pituitary proliferative response and gene expression patterns between Fischer 344 and Brown Norway rats
- 1Comparative Veterinary Pharmacology and Toxicology Laboratory, School of Veterinary Medicine, Iwate University, 3-18-8 Ueda, Morioka-shi, Iwate 020-8550, Japan
Abstract
Estrogen-induced pituitary proliferative lesions exhibit marked strain differences in rats; however, the molecular basis of this resistance remains unclear. This study compared estrogen-responsive Fischer 344 (F344) rats with resistant Brown Norway (BN) rats to identify candidate genes associated with resistance. Male F344 and BN rats received subcutaneous estradiol valerate (EV, 20 mg/kg) either as a single dose/as five injections over 9 weeks, with sampling performed one day after the final treatment; corn oil-treated animals served as controls. Macroscopic examination, pituitary weight measurement, and histopathology were conducted, followed by transcriptome analysis using RNA sequencing, and validation by quantitative polymerase chain reaction and immunohistochemistry. After 9 weeks of estradiol valerate treatment, F344 rats exhibited pronounced pituitary enlargement, accompanied by dark reddish discoloration with diffuse hyperplasia, characterized by hypertrophy of acidophilic cells, vascular congestion, and brown pigment deposition. In contrast, the BN rats showed only a slight increase in pituitary weight and no overt histological alterations. Transcriptome analysis identified 27 genes consistently regulated in BN rats after both single-dose and 9-week EV treatment but not significantly changed in F344 rats. Changes in the selected candidate genes were confirmed by quantitative polymerase chain reaction. Immunohistochemistry demonstrated increased RASA4 immunoreactivity and reduced GNB3 immunoreactivity in BN rats following treatment. These findings indicate that BN rats exhibit pituitary-specific resistance, potentially mediated by the strain-dependent transcriptional modulation of Ras-related pathways.
Related
- Integrated pituitary adaptations to the low estrogen state.
- Androgen receptor expression is associated with a distinct low-proliferative phenotype in triple-negative breast cancer
- Association between adipose (pro)renin receptor expression and growth hormone deficiency in patients with non-functioning hypothalamic-pituitary masses
- Pharmacological chromatin remodeling enhances response to estrogen therapy in ER + breast cancer
- Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features.
BibTeX
@article{inoue2026strain,
title = {{Strain differences in estrogen-induced pituitary proliferative response and gene expression patterns between Fischer 344 and Brown Norway rats}},
author = {Satoshi Inoue and Hirofumi Hatakeyama and Miki Masatsugu and Riko Ito and Koji Ono and Toko Maehara and Hiroshi Satoh},
journal = {Journal of Toxicologic Pathology},
year = {2026},
month = jul,
doi = {10.1293/tox.2026-0015},
url = {https://doi.org/10.1293/tox.2026-0015},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Strain differences in estrogen-induced pituitary proliferative response and gene expression patterns between Fischer 344 and Brown Norway rats
AU - Satoshi Inoue
AU - Hirofumi Hatakeyama
AU - Miki Masatsugu
AU - Riko Ito
AU - Koji Ono
AU - Toko Maehara
AU - Hiroshi Satoh
PY - 2026
DA - 2026/07/28
JO - Journal of Toxicologic Pathology
DO - 10.1293/tox.2026-0015
UR - https://doi.org/10.1293/tox.2026-0015
AB - Estrogen-induced pituitary proliferative lesions exhibit marked strain differences in rats; however, the molecular basis of this resistance remains unclear. This study compared estrogen-responsive Fischer 344 (F344) rats with resistant Brown Norway (BN) rats to identify candidate genes associated with resistance. Male F344 and BN rats received subcutaneous estradiol valerate (EV, 20 mg/kg) either as a single dose/as five injections over 9 weeks, with sampling performed one day after the final treatment; corn oil-treated animals served as controls. Macroscopic examination, pituitary weight measurement, and histopathology were conducted, followed by transcriptome analysis using RNA sequencing, and validation by quantitative polymerase chain reaction and immunohistochemistry. After 9 weeks of estradiol valerate treatment, F344 rats exhibited pronounced pituitary enlargement, accompanied by dark reddish discoloration with diffuse hyperplasia, characterized by hypertrophy of acidophilic cells, vascular congestion, and brown pigment deposition. In contrast, the BN rats showed only a slight increase in pituitary weight and no overt histological alterations. Transcriptome analysis identified 27 genes consistently regulated in BN rats after both single-dose and 9-week EV treatment but not significantly changed in F344 rats. Changes in the selected candidate genes were confirmed by quantitative polymerase chain reaction. Immunohistochemistry demonstrated increased RASA4 immunoreactivity and reduced GNB3 immunoreactivity in BN rats following treatment. These findings indicate that BN rats exhibit pituitary-specific resistance, potentially mediated by the strain-dependent transcriptional modulation of Ras-related pathways.
SN - 0914-9198
SN - 1881-915X
ER -